表紙
市場調查報告書
商品編碼
1069632

血栓溶解劑的全球市場:各類型,各用途,各流通管道,各地區,競爭預測及機會,2017年∼2027年

Global Clot Buster Drugs Market, By Type, By Application, By Distribution Channel, By Region, Competition Forecast and Opportunities, 2017-2027

出版日期: | 出版商: TechSci Research | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

  • 全貌
  • 簡介
  • 目錄
簡介

全球血栓溶解劑的市場規模,預計在預測期間內以驚異性的速度擴大。

該市場的成長,起因於心血管疾病的發生率的上升和醫藥品的技術創新的日益增加。還有死亡率的上升和製藥產業的進步,刺激全球血栓溶解劑市場成長。此外,市場參與企業,為了開發有效安全的醫藥品增加研究開發的投資,預計促進該市場的成長。

本報告提供全球血栓溶解劑市場相關調查,市場概要,以及各類型,各用途,各流通管道,各地區的趨勢,競爭趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 摘要整理

第4章 COVID-19對全球血栓溶解劑市場的影響

第5章 客戶的迴響

第6章 臨床試驗

  • 進行中的臨床試驗
  • 完成的臨床試驗
  • 中斷的臨床試驗
  • 臨床試驗分析

第7章 專利分析

  • 專利給予(2016年∼2020年)
  • 專利申請

第8章 全球血栓溶解劑市場預測

  • 市場規模與預測
  • 市場佔有率與預測
    • 各類型(纖維蛋白特異性藥物,非纖維蛋白特異性藥物)
    • 各用途(心肌梗塞,肺動脈栓塞,深部靜脈血栓症,急性缺血性腦中風,其他)
    • 各流通管道(零售藥局,醫院藥局,線上藥局)
    • 各企業(2021年)
    • 各地區
  • 產品市場地圖

第9章 北美的血栓溶解劑市場預測

  • 市場規模與預測
  • 市場佔有率與預測
  • 北美:各國分析

第10章 歐洲的血栓溶解劑市場預測

  • 市場規模與預測
  • 市場佔有率與預測
  • 歐洲:各國分析

第11章 亞太地區的血栓溶解劑市場預測

  • 市場規模與預測
  • 市場佔有率與預測
  • 亞太地區:各國分析

第12章 南美的血栓溶解劑市場預測

  • 市場規模與預測
  • 市場佔有率與預測
  • 南美:各國分析

第13章 中東、非洲的血栓溶解劑市場預測

  • 市場規模與預測
  • 市場佔有率與預測
  • 中東、非洲:各國分析

第14章 市場動態

  • 促進因素
  • 課題

第15章 市場趨勢與發展

第16章 競爭情形

  • F. Hoffmann-La Roche AG
  • Taj Pharmaceuticals Limited
  • Eumedica Pharmaceuticals SA
  • SEDICO Pharmaceutical Company
  • Mochida Pharmaceutical Co., Ltd
  • Medac GmbH
  • Microbix Biosystems Inc
  • Crinos S.p.A.

第17章 策略性推薦事項

目錄
Product Code: 8207

The global clot buster drugs market is anticipated to register growth at a formidable rate during the forecast period. The market growth can be attributed to the rising incidences of cardiovascular disorders and rising innovation in pharmaceutical drugs. Clot buster drugs are used to prevent ongoing damage to the heart during a heart attack or address the clots formed in other parts of blood vessels in the body. Increasing mortality rates and the advancing pharmaceutical industry are fueling the growth of the global clot buster drugs market. Additionally, market players are increasingly investing in R&D for developing effective and safer pharmaceutical drugs, which is expected to drive the growth of the global clot buster drugs market. A sedentary lifestyle, consumption of junk food, smoking, and drinking habits are the primary causes of cardiovascular disorders. Stroke is one of the leading causes of death worldwide. Hence, government authorities are taking initiatives for the development of therapeutic drugs to reduce the mortality rates, which is anticipated to boost the global clot buster drugs market. Technological developments in the healthcare sector is contributing to the better safety and efficacy of the drugs, which is further accelerated to propel the global clot buster drugs market. However, increasing awareness of the global population towards maintaining a healthy lifestyle might hinder the development of the global clot buster drugs market.

The global clot buster drugs market is segmented on the basis of type, application, distribution channel, regional distribution, and competitive landscape. Based on application, the market is further segmented into myocardial infarction, pulmonary embolism, deep vein thrombosis, acute ischemic strokes, and others. The acute ischemic strokes segment is anticipated to dominate the global clot buster drugs market during the forecast period due to rising incidences of ischemic strokes worldwide. Around 80% of all strokes are ischemic strokes where brain blood vessels become narrowed or blocked.

Major players operating in the global clot buster drugs market are F. Hoffmann-La Roche AG, Taj Pharmaceuticals Limited, Eumedica Pharmaceuticals SA, SEDICO Pharmaceutical Company, Mochida Pharmaceutical Co., Ltd, Medac GmbH, Microbix Biosystems Inc, Crinos S.p.A, etc.

Years considered for this report:

Historical Years: 2017-2020

Base Year: 2021

Estimated Year: 2022E

Forecast Period: 2023F-2027F

Objective of the Study:

  • To analyze the historical growth in the market size of global clot buster drugs market from 2017 to 2021.
  • To estimate and forecast the market size of global clot buster drugs market from 2022E to 2027F and growth rate until 2027F.
  • To classify and forecast global clot buster drugs market based on type, application, distribution channel, region, and competitive landscape.
  • To identify dominant region or segment in the global clot buster drugs market.
  • To identify drivers and challenges for global clot buster drugs market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global clot buster drugs market.
  • To identify and analyze the profile of leading players operating in global clot buster drugs market.
  • To identify key sustainable strategies adopted by market players in global clot buster drugs market.

Report Scope:

In this report, global clot buster drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Clot Buster Drugs Market, By Type:

Fibrin Specific Drugs

  • Tissue Plasminogen Activator
  • Reteplase
  • Tenecteplase
  • Others

Non-Fibrin Specific Drugs

  • Urokinase
  • Streptokinase
  • Plasminogen Activating Complex
  • Clot Buster Drugs Market, By Application:

Myocardial Infarction

Pulmonary Embolism

Deep Vein Thrombosis

Acute Ischemic Strokes

Others

  • Clot Buster Drugs Market, By Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

  • Clot Buster Drugs Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

South America

  • Brazil
  • Argentina
  • Colombia

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global clot buster drugs market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Clot buster drug manufacturing companies/partners
  • Suppliers/Distributers
  • End-Users
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to global clot buster drugs market

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, partners, end users, etc. besides allowing them in strategizing investments and capitalizing on market opportunities.

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global clot buster drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Clot Buster Drugs Market

5. Voice of Customer

  • 5.1. Preference, By Drug Type
  • 5.2. Factors Contributing to Higher Demand for Clot Buster Drugs
  • 5.3. Barriers to Adoption of Clot Buster Drugs
  • 5.4. Brand Awareness

6. Clinical Trials

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Clinical Trial Analysis

7. Patent Analysis

  • 7.1. Patent Granted (2016-2020)
  • 7.2. Patent Applications Filed

8. Global Clot Buster Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 8.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 8.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 8.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 8.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 8.2.4. By Company (2021)
    • 8.2.5. By Region
  • 8.3. Product Market Map

9. North America Clot Buster Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 9.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 9.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 9.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 9.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 9.2.4. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Clot Buster Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Mexico Clot Buster Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Canada Clot Buster Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. Europe Clot Buster Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 10.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 10.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 10.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 10.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 10.2.4. By Country
  • 10.3. Europe: Country Analysis
    • 10.3.1. France Clot Buster Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Germany Clot Buster Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. United Kingdom Clot Buster Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel
    • 10.3.4. Italy Clot Buster Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Application
        • 10.3.4.2.3. By Distribution Channel
    • 10.3.5. Spain Clot Buster Drugs Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By Application
        • 10.3.5.2.3. By Distribution Channel

11. Asia-Pacific Clot Buster Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 11.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 11.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 11.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 11.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 11.2.4. By Country
  • 11.3. Asia-Pacific: Country Analysis
    • 11.3.1. China Clot Buster Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Application
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. India Clot Buster Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Application
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. South Korea Clot Buster Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Application
        • 11.3.3.2.3. By Distribution Channel
    • 11.3.4. Japan Clot Buster Drugs Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Type
        • 11.3.4.2.2. By Application
        • 11.3.4.2.3. By Distribution Channel
    • 11.3.5. Australia Clot Buster Drugs Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Type
        • 11.3.5.2.2. By Application
        • 11.3.5.2.3. By Distribution Channel

12. South America Clot Buster Drugs Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 12.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 12.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 12.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 12.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 12.2.4. By Country
  • 12.3. South America: Country Analysis
    • 12.3.1. Brazil Clot Buster Drugs Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Type
        • 12.3.1.2.2. By Application
        • 12.3.1.2.3. By Distribution Channel
    • 12.3.2. Argentina Clot Buster Drugs Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Type
        • 12.3.2.2.2. By Application
        • 12.3.2.2.3. By Distribution Channel
    • 12.3.3. Colombia Clot Buster Drugs Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Type
        • 12.3.3.2.2. By Application
        • 12.3.3.2.3. By Distribution Channel

13. Middle East and Africa Clot Buster Drugs Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value
  • 13.2. Market Share & Forecast
    • 13.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 13.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 13.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 13.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 13.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 13.2.4. By Country
  • 13.3. Middle East and Africa: Country Analysis
    • 13.3.1. South Africa Clot Buster Drugs Market Outlook
      • 13.3.1.1. Market Size & Forecast
        • 13.3.1.1.1. By Value
      • 13.3.1.2. Market Share & Forecast
        • 13.3.1.2.1. By Type
        • 13.3.1.2.2. By Application
        • 13.3.1.2.3. By Distribution Channel
    • 13.3.2. Saudi Arabia Clot Buster Drugs Market Outlook
      • 13.3.2.1. Market Size & Forecast
        • 13.3.2.1.1. By Value
      • 13.3.2.2. Market Share & Forecast
        • 13.3.2.2.1. By Type
        • 13.3.2.2.2. By Application
        • 13.3.2.2.3. By Distribution Channel
    • 13.3.3. UAE Clot Buster Drugs Market Outlook
      • 13.3.3.1. Market Size & Forecast
        • 13.3.3.1.1. By Value
      • 13.3.3.2. Market Share & Forecast
        • 13.3.3.2.1. By Type
        • 13.3.3.2.2. By Application
        • 13.3.3.2.3. By Distribution Channel
    • 13.3.4. Egypt Clot Buster Drugs Market Outlook
      • 13.3.4.1. Market Size & Forecast
        • 13.3.4.1.1. By Value
      • 13.3.4.2. Market Share & Forecast
        • 13.3.4.2.1. By Type
        • 13.3.4.2.2. By Application
        • 13.3.4.2.3. By Distribution Channel

14. Market Dynamics

  • 14.1. Drivers
  • 14.2. Challenges

15. Market Trends & Developments

16. Competitive Landscape

  • 16.1. F. Hoffmann-La Roche AG
  • 16.2. Taj Pharmaceuticals Limited
  • 16.3. Eumedica Pharmaceuticals SA
  • 16.4. SEDICO Pharmaceutical Company
  • 16.5. Mochida Pharmaceutical Co., Ltd
  • 16.6. Medac GmbH
  • 16.7. Microbix Biosystems Inc
  • 16.8. Crinos S.p.A.

17. Strategic Recommendations